Applications can be submitted at any time.
The Foundation’s aim with this funding measure is to find projects that have the potential to lead to fundamental discoveries that are groundbreaking for an entire field of research. This could be, for example:
- evidence of a causal connection that was previously lacking,
- testing of a previously non-existent or unworkable hypothesis,
- questioning of a previously generally accepted theory, a “proof of principle” or a “first-in-man” examination of an innovative intervention approach,
- or even a clinical trial that has the potential to significantly transform guidelines (with the exception of phase III pharmaceutical trials).
It is in the nature of going beyond the boundaries of previous limits of knowledge that such key projects can often not be assigned to any particular field or any thematically defined call for applications.
Addressees Eligible to Apply
Applications can be made by scientists who have gained international recognition in their area of research and who have had outstanding publications in relevant fields. The applicants should provide convincing evidence that their work group is particularly suited – also in the competitive international context – to solving the problem at hand through the interplay between expertise, preparatory work or even infrastructure.
Both human and material resources may be applied for as necessary and scientifically justified for implementation of the planned project. The funds shall be allocated in a two-stage procedure. Prior to the time-consuming formulation of a full application, a draft proposal should be submitted first. The topicality and potential of the project idea as a key project shall be evaluated based on this draft.
Project managers of an EKFS funding project that is currently ongoing shall only be eligible to make a new application after completion and publication of the results of that project.
Overview of key projects running since 2019
Key project "Effects of adaptive servoventilation on ventricular arrhythmias in heart failure patients with either obstructive or central sleep apnea – a substudy of the ADVENT-HF trial" (2019)
Key project "Inducing blood stage immunity by repeated Plasmodium falciparum sporozoite infection" (2019)
Key project "Monitoring of therapy effects and detection of minimal residual disease (MRD) in adult acute myeloid leukemia (AML) with DNMT3A mutation within the framework of innovative study concepts of the AMLSG (AMLSG 09-09, AMLSG 12-09 and ALMSG 16-10)" (2019)